Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.

Document types check

Please use this identifier to cite or link to this item: https://hdl.handle.net/20.500.12530/24205

Title:	Real-life data in 115 chronic migraine patients treated with Onabotulinumtoxin A during more than one year.
Authors:	Aicua-Rapun, I Martínez-Velasco, E Rojo, A Hernando, A Ruiz, M Carreres, A Porqueres, E Herrero, S Iglesias, F Guerrero, A L View more
Keywords:	Chronic Migraine Medication overuse OnabotulinumtoxinA Preventatives Real-life data View more
Mesh:	Adolescent Adult Aged Botulinum Toxins, Type A Chronic Disease Drug Administration Schedule Female Humans Male Middle Aged Migraine Disorders Neuromuscular Agents Prospective Studies Retrospective Studies Statistics as Topic Treatment Outcome Young Adult View more
Issue Date:	Dec-2016
Citation:	J Headache Pain.2016 Dec;(17)1:112
Abstract:	OnabotulinumtoxinA (OnabotA) is effective in Chronic Migraine (CM) during first year of treatment and longer. In real clinical setting, CM patients with acute Medication Overuse (MO) or concurrently receiving oral preventatives are treated with OnabotA. We aim to assess evolution of CM patients beyond first year on OnabotA.
PMID:	27957623
URI:	https://hdl.handle.net/20.500.12530/24205
Rights:	openAccess
Appears in Collections:	Fundaciones e Institutos de Investigación > IIS H. U. Ramón y Cajal > Artículos

Files in This Item:

File	Description	Size	Format
PMC5153399.pdf		425.29 kB	Adobe PDF	View/Open